Business
ARIUS announces first quarter fiscal 2008 financial results
TORONTO, April 11 /CNW/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering an...
About this update from Affinity Metals Corp
[{"type":"text","content":"\n\n\n\nTORONTO, April 11 /CNW/ - ARIUS Research Inc., (TSX: ARI), a\nbiotechnology company discovering and developing the next wave of antibody\ntherapeutics, today announced its financial and operational results for the\nfirst fiscal quarter of 2008, ended February 29, 2008.\n\n\n"During the quarter, we continued to focus on advancing our antibody\ndrugs efficiently and rapidly towards human clinical trials. Most\nsignificantly, we completed our pre-IND meeting with the US FDA for our lead\nCD44 Cancer Stem Program," said Dr. David Young, President and CEO of ARIUS.\n"We also presented new findings from our lead programs, including data from\nour CD9 Cancer Stem Cell program in collaboration with Dr. John Dick, a\npioneer in the cancer stem cell field. Maintaining this momentum, five ARIUS\nabstracts have been selected for presentation in the upcoming AACR Annual\nmeeting this month, demonstrating the scientific community's ongoing interest\nin our programs and the high quality of our research."\n\n\nProgram Updates:\n\nCD44 Cancer Stem Cell Program\n - Selected to present two CD44-focused posters at AACR the American\n Association for Cancer Research (AACR) Annual Meeting held from\n April 12-16, 2008 in San Diego, California.\n - Held meeting with FDA to discuss plans for the upcoming\n IND submission.\n - Prepared to file a Phase I IND application and begin human\n clinical trials for the CD44 Cancer Stem Cell program in 2008.\n\nTrop-2 Signal Transduction Program\n - Completed first toxicology studies.\n - Selected to present a Trop-2-focused poster at AACR Annual\n Meeting.\n - Engaged Laureate Pharma Inc. for cGMP manufacturing of humanized\n antibody for Phase 1 clinical supply. A cell line producing the\n humanized anti-Trop-2 antibody was successfully transferred to\n Laureate.\n - Preparing for a pre-IND meeting with the FDA planned for the third\n quarter of 2008, and the filing of a Phase I IND application\n anticipated in late 2008.\n\nCD59 Complement Inhibitor Program\n - Selected to present a CD59-focused poster at AACR Annual Meeting.\n - Generated a cell line producing humanized CD59 antibody that\n successfully retained binding characteristics and potent in vivo\n activity.\n - Preparing to perform preclinical toxicology studies planned for\n 2008 in preparation for filing a Phase I IND ap...